Keywords: prostatic neoplasms; biomarkers; early detection of cancer; prognosis; DRE; digital rectal examination; FDA; Food and Drug Administration; mpMRI; multiparametric MRI; MRI; magnetic resonance imaging; NCCN®; National Comprehensive Cancer Network®; PCA3;